Last reviewed: May 14, 2026 Last updated: May 14, 2026 Written by: Jay Hastings , CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Both Semaglutide GLP-1 and Liraglutide are glucagon-like peptide-1 (GLP-1) receptor agonists, which are frequently used in managing type 2 diabetes and are approved for weight management in adults with obesity or overweight with obesity-related comorbidities
Presented for research literature review only Kripke DF et al
BPC-157 / TB-500 is a research peptide blend combining two well-studied synthetic peptides: Body Protection Compound-157 (BPC-157) and Thymosin Beta-4 fragment TB-500. BPC-157 is a stable gastric pentadecapeptide originally derived from human gastric juice, while TB-500 is a synthetic peptide modeled after the naturally occurring thymosin beta-4. Together, this blend is formulated for laboratory research focused on tissue repair, angiogenesis, and cellular regeneration pathways
Our goal is to ensure Islanders have access to the most effective coverage while maintaining the sustainability of our drug programs. GLP-1 drugs can help prepare for surgery Evers says using GLP-1 medications can be beneficial in conjunction with bariatric surgery a procedure that reduces the size of the stomach to help those with obesity manage their weight and overall health
Theoretical immunogenicity flagged by FDA in the Category 2 listing